APP and Alzheimer disease: Numerous studies reported that treatment of APP-transgenic mice with LXR or RXR agonists decreased Aβ load126,297-301 and/or improved cognitive impairment.126,297,298,300 Other studies reported cognitive improvement without significant changes in Aβ load in APP-transgenic mice treated with LXR agonists.302,303 LXR and RXR agonists have already been described extensively as potential therapeutics in the literature, also with respect to AD.304 The present review will focus on those agonists that were reported in clear association with ABCA1.